Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling
Rio Dumitrascu(Justus-Liebig-Universität Gießen), Ralph T. Schermuly(Justus-Liebig-Universität Gießen), Knut Beuerlein(Monash University), Eva Dony(University of Vienna), Harald Schmidt(Maastricht University), Norbert Weißmann(Cardio-Pulmonary Institute), Hossein Ardeschir Ghofrani(Justus-Liebig-Universität Gießen), Friedrich Grimminger(Justus-Liebig-Universität Gießen), Werner Seeger(Justus-Liebig-Universität Gießen), Johannes‐Peter Stasch(Bayer (Germany)), Mark Jean Gnoth(Bayer (Germany))
Cited by 222
Related Papers
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
Clinical classification of pulmonary hypertension
|Journal of the American College of Cardiology|2004|1.9k
Inhaled Iloprost for Severe Pulmonary Hypertension
|New England Journal of Medicine|2002|1.8k
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
|New England Journal of Medicine|2013|1.4k
Reversal of experimental pulmonary hypertension by PDGF inhibition
|Journal of Clinical Investigation|2005|1.1k